Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very comm...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2022-07-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2095 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|